Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Farmers Insurance
Accenture
Baxter
Federal Trade Commission
Julphar
Queensland Health
Covington

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020667

« Back to Dashboard

NDA 020667 describes MIRAPEX, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are four patents protecting this drug and five Paragraph IV challenges. Additional details are available on the MIRAPEX profile page.

The generic ingredient in MIRAPEX is pramipexole dihydrochloride. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the pramipexole dihydrochloride profile page.
Summary for 020667
Tradename:MIRAPEX
Applicant:Boehringer Ingelheim
Ingredient:pramipexole dihydrochloride
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 020667
Mechanism of ActionDopamine Agonists
Suppliers and Packaging for NDA: 020667
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0101 N 0597-0101-90
MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0183 N 0597-0183-90

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.125MG
Approval Date:Jul 1, 1997TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 16, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
Patent:➤ Try a Free TrialPatent Expiration:Jan 16, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.25MG
Approval Date:Jul 1, 1997TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 16, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

Expired US Patents for NDA 020667

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-004 Jul 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-002 Jul 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-001 Jul 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-007 Jul 30, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Johnson and Johnson
Baxter
Chubb
Covington
Harvard Business School
Dow
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.